Pidilizumab

Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].

Product Specifications

CAS Number

[1036730-42-3]

Product Name Alternative

CT-011; MDV9300

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pidilizumab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Pidilizumab]

Molecular Weight

(144.626 kDa)

References & Citations

[1]Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15 (1) :69-77.|[2]Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40 (14) :6450-6462.